메뉴 건너뛰기




Volumn 12, Issue 1, 2013, Pages 30-35

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

(17)  Urquijo, Juan José a   Diago, Moisés a   Boadas, Jaume b   Planas, Ramón c   Solá, Ricard d   del Olmo, Juan Angel e   Crespo, Javier f   Erdozaín, José Carlos g   Antón, María Dolores h   Arocena, Carlos i   Suarez, Dolores j   Giné, Josep k   Barrera, Josep M l   García Samaniego, Javier g   Perez, Ricardo m   Dalmau, Blai n   Montoro, Miguel o  


Author keywords

Peginterferon; Ribavirin; Sustained viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

EID: 84878768400     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31382-1     Document Type: Article
Times cited : (8)

References (40)
  • 1
    • 0033060563 scopus 로고    scopus 로고
    • Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
    • WHO
    • WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999: 6: 35-47.
    • (1999) J Viral Hepat , vol.6 , pp. 35-47
  • 2
    • 84910001182 scopus 로고    scopus 로고
    • WHO, Available at: URL
    • o 164. Available at: URL.
    • o 164
  • 4
    • 26444432835 scopus 로고    scopus 로고
    • Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6
    • Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005: 3: S97-S101.
    • (2005) Clin Gastroenterol Hepatol , vol.3
    • Nguyen, M.H.1    Keeffe, E.B.2
  • 5
    • 0030855655 scopus 로고    scopus 로고
    • The relationship of histology to genotype in chronic HCV infection
    • Booth JC, Foster GR, Levine T, Thomas HC, Goldin RD. The relationship of histology to genotype in chronic HCV infection. Liver 1997: 17: 144-51.
    • (1997) Liver , vol.17 , pp. 144-151
    • Booth, J.C.1    Foster, G.R.2    Levine, T.3    Thomas, H.C.4    Goldin, R.D.5
  • 6
    • 9044246268 scopus 로고
    • Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C
    • Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T, Hashimoto M, et al. Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 1995: 23: 648-53.
    • (1995) J Hepatol , vol.23 , pp. 648-653
    • Chayama, K.1    Tsubota, A.2    Arase, Y.3    Saitoh, S.4    Ikeda, K.5    Matsumoto, T.6    Hashimoto, M.7
  • 7
    • 0030225412 scopus 로고    scopus 로고
    • Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4
    • el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996; 3: 261-4.
    • (1996) J Viral Hepat , vol.3 , pp. 261-264
    • el-Zayadi, A.1    Simmonds, P.2    Dabbous, H.3    Prescott, L.4    Selim, O.5    Ahdy, A.6
  • 8
    • 18344381087 scopus 로고    scopus 로고
    • Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes
    • Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005; 10: 1-11.
    • (2005) Antivir Ther , vol.10 , pp. 1-11
    • Hnatyszyn, H.J.1
  • 11
    • 26944498262 scopus 로고    scopus 로고
    • High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain
    • Martinez SM, Delgado MB, Castroagudin JF, Aguilera A. High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain. J Clin Microbiol 2005; 43: 5403-4.
    • (2005) J Clin Microbiol , vol.43 , pp. 5403-5404
    • Martinez, S.M.1    Delgado, M.B.2    Castroagudin, J.F.3    Aguilera, A.4
  • 12
    • 34247094400 scopus 로고    scopus 로고
    • Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: An update and report of a new method of HCV genotyping
    • Cenci M, Massi M, Alderisio M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of a new method of HCV genotyping. Anticancer Res 2007; 27: 1219-22.
    • (2007) Anticancer Res , vol.27 , pp. 1219-1222
    • Cenci, M.1    Massi, M.2    Alderisio, M.3    De Soccio, G.4    Recchia, O.5
  • 13
    • 0037827263 scopus 로고    scopus 로고
    • Le virus de l'hepatite C de génotype 4. Caracteristiques épidemiologiques et réponse aux traitments antiviraux
    • Castera L, Morice Y, Grando V, Bon C, Deny P, Roulot D. Le virus de l'hepatite C de génotype 4. Caracteristiques épidemiologiques et réponse aux traitments antiviraux. Gastroenterol Clin Biol 2003; 27: 596-604.
    • (2003) Gastroenterol Clin Biol , vol.27 , pp. 596-604
    • Castera, L.1    Morice, Y.2    Grando, V.3    Bon, C.4    Deny, P.5    Roulot, D.6
  • 14
  • 15
    • 42249110672 scopus 로고    scopus 로고
    • Hepatitis C genotype 4: What we know and what we don't yet know
    • Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47: 1371-83.
    • (2008) Hepatology , vol.47 , pp. 1371-1383
    • Kamal, S.M.1    Nasser, I.A.2
  • 17
    • 34547878036 scopus 로고    scopus 로고
    • Treatment of genotype 4 patients
    • Diago-Madrid M. Treatment of genotype 4 patients. Gastroenterol Hepatol 2006; 29: 5.
    • (2006) Gastroenterol Hepatol , vol.29 , pp. 5
    • Diago-Madrid, M.1
  • 18
    • 48749099989 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    • Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
    • (2008) Gastroenterology , vol.135 , pp. 451-458
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3    Gschwantler, M.4    Maieron, A.5    Brunner, H.6    Stauber, R.7
  • 19
    • 75449111848 scopus 로고    scopus 로고
    • Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response
    • Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-12, 512 e1.
    • (2010) Gastroenterology , vol.138
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3    Maieron, A.4    Hofer, H.5    Stauber, R.6    Gschwantler, M.7
  • 20
    • 19944409281 scopus 로고    scopus 로고
    • Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4
    • Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, Al-Ahdal MN, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568-74.
    • (2004) Liver Int , vol.24 , pp. 568-574
    • Alfaleh, F.Z.1    Hadad, Q.2    Khuroo, M.S.3    Aljumah, A.4    Algamedi, A.5    Alashgar, H.6    Al-Ahdal, M.N.7
  • 21
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
    • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
    • (1998) N Engl J Med , vol.339 , pp. 1485-1492
    • McHutchison, J.G.1    Gordon, S.C.2    Schiff, E.R.3    Shiffman, M.L.4    Lee, W.M.5    Rustgi, V.K.6    Goodman, Z.D.7
  • 22
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
    • (1998) Lancet , vol.352 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3    Niederau, C.4    Minuk, G.S.5    Ideo, G.6    Bain, V.7
  • 23
    • 0035923425 scopus 로고    scopus 로고
    • Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha
    • Sherman M, Marinos G, Sedarati F. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2001; 135: 927-8.
    • (2001) Ann Intern Med , vol.135 , pp. 927-928
    • Sherman, M.1    Marinos, G.2    Sedarati, F.3
  • 24
    • 3042673841 scopus 로고    scopus 로고
    • Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin
    • Esmat G, Abouzied AM, Abdel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin. Hepatology 2003; 38.
    • (2003) Hepatology , pp. 38
    • Esmat, G.1    Abouzied, A.M.2    Abdel-Aziz, F.3    Strickland, T.4
  • 26
    • 0033965331 scopus 로고    scopus 로고
    • Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
    • The ALGOVIRC Project Group
    • Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211-8.
    • (2000) Hepatology , vol.31 , pp. 211-218
    • Poynard, T.1    McHutchison, J.2    Goodman, Z.3    Ling, M.H.4    Albrecht, J.5
  • 28
    • 0346727453 scopus 로고    scopus 로고
    • Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin
    • Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004; 140: 72-3.
    • (2004) Ann Intern Med , vol.140 , pp. 72-73
    • Diago, M.1    Hassanein, T.2    Rodes, J.3    Ackrill, A.M.4    Sedarati, F.5
  • 30
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6    Ramadori, G.7
  • 31
    • 78349285127 scopus 로고    scopus 로고
    • Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin
    • Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30: 1259-69.
    • (2010) Liver Int , vol.30 , pp. 1259-1269
    • Asselah, T.1    Estrabaud, E.2    Bieche, I.3    Lapalus, M.4    De Muynck, S.5    Vidaud, M.6    Saadoun, D.7
  • 32
    • 0030885469 scopus 로고    scopus 로고
    • Factors predictive of a beneficial response to therapy of hepatitis C
    • Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122S-127S.
    • (1997) Hepatology , vol.26
    • Davis, G.L.1    Lau, J.Y.2
  • 33
    • 84864362846 scopus 로고    scopus 로고
    • An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS)
    • Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, et al. An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS). J Gastroenterol Hepatol 2011.
    • (2011) J Gastroenterol Hepatol
    • Ogawa, E.1    Furusyo, N.2    Kajiwara, E.3    Takahashi, K.4    Nomura, H.5    Tanabe, Y.6    Satoh, T.7
  • 36
    • 79958816097 scopus 로고    scopus 로고
    • Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
    • Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
    • (2011) J Hepatol , vol.55 , pp. 69-75
    • Fried, M.W.1    Hadziyannis, S.J.2    Shiffman, M.L.3    Messinger, D.4    Zeuzem, S.5
  • 37
    • 34250320980 scopus 로고    scopus 로고
    • Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    • Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 832-836
    • Yu, J.W.1    Wang, G.Q.2    Sun, L.J.3    Li, X.G.4    Li, S.C.5
  • 38
    • 79960364557 scopus 로고    scopus 로고
    • IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
    • Gonzalez SA, Keeffe EB. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (NY) 2011; 7: 366-73.
    • (2011) Gastroenterol Hepatol (NY) , vol.7 , pp. 366-373
    • Gonzalez, S.A.1    Keeffe, E.B.2
  • 39
    • 77953881002 scopus 로고    scopus 로고
    • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    • Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9 e18.
    • (2010) Gastroenterology , vol.139
    • Thompson, A.J.1    Muir, A.J.2    Sulkowski, M.S.3    Ge, D.4    Fellay, J.5    Shianna, K.V.6    Urban, T.7
  • 40
    • 84855232740 scopus 로고    scopus 로고
    • The future for the treatment of genotype 4 chronic hepatitis C
    • Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 146-50.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 146-150
    • Esmat, G.1    El Raziky, M.2    El Kassas, M.3    Hassany, M.4    Gamil, M.E.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.